Drug-related problems : evaluation of a classification system in the daily practice of a Swiss University Hospital by Lampert, Markus L. et al.
RESEARCH ARTICLE
Drug-related problems: evaluation of a classiﬁcation system
in the daily practice of a Swiss University Hospital
Markus L. LampertÆStephan KraehenbuehlÆ
Balthasar L. Hug
Received: 7 August 2007 / Accepted: 10 March 2008 / Published online: 21 March 2008
Springer Science+Business Media B.V. 2008
Abstract Aim To evaluate the Pharmaceutical Care
Network Europe (PCNE) classiﬁcation system as a tool for
documenting the impact of a hospital clinical pharmacol-
ogy service.SetingTwo medical wards comprising totaly
85 beds in a university hospital.Main outcome measure
Number of events classiﬁed with the PCNE-system, their
acceptance by the medical staf and cost implications.
MethodsClinical pharmacy review of pharmacotherapy on
ward rounds and from case notes were documented, and
identiﬁed drug-related problems (DRPs) were classiﬁed
using the PCNE system version 5.00.ResultsDuring 70
observation days 216 interventions were registered of
which 213 (98.6%) could be classiﬁed: 128 (60.1%) were
detected by reviewing the case notes, 33 (15.5%) on ward
rounds, 32 (15.0%) by direct reporting to the clinical
pharmacist (CP), and 20 (9.4%) on non-formulary pre-
scriptions. Of 148 suggested interventions by the CP 123
(83.0%) were approved by the responsible physician, 12
ADR reports (8.1%) were submited to the local pharma-
covigilance centre and 31 (20.9%) speciﬁc information
given without further need for action. An evaluation of the
DRPs showed that direct drug costs of€2,058 within the
study period or€10,731 per year could be avoided.
ConclusionWe consider the PCNE system to be a practical
tool in the hospital seting, which demonstrates the values
of a clinical pharmacy service in terms of identifying and
reducing DRPs and also has the potential to reduce pre-
scribing costs.
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Impact of ﬁndings on practice
• The PCNE-classiﬁcation system is suitable for daily
hospital practice and a useful tool for documenting
clinical pharmacy activities.
• Structured documentation with the PCNE-classiﬁcation
alows performance measurement of clinical pharmacy
services.
Introduction
Drug-related problems are a major safety issue for hospi-
talized patients. A review of the literature from 1990 to
2005 found that on average 8% of hospitalised patients
experience an adverse drug event (ADE), and 5–10% of al
drug prescriptions or drug applications are eroneous [1]. In
general internal medicine 14.6% of hospitalized patients
and approximately 12% to 17% of patients after discharge
experience ADEs [2,3]. Interventions by clinical pharma-
cists have been shown to be efective in reducing DRPs with
positive outcomes on the number of ADEs, medication
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appropriateness and resource use. A systematic literature
review of controled studies evaluating the efects of
interventions by clinical pharmacists on hospitalized adults
found that ADEs, adverse drug reactions (ADR) and MEs
were reduced in 7 of 12 trials that included these outcomes
[4]. Medication adherence, knowledge, and appropriateness
of drug use improved in 7 of 11 studies and the length of
hospital stay was shortened in 9 of 17 trials.
From an economic point of view clinical pharmacy
services are also favourable. A summary of literature from
1996 to 2000 found 16 studies reporting a cost-beneﬁt ratio
ranging from 1.7:1 to 17:1 with a median of 4.68:1 [5].
In many of these studies, however, deﬁnitions of
detected or prevented problems such as ADRs, ADEs,
medication erors or prescribing erors are not consistent.
This may cause difﬁculties in documentation and classiﬁ-
cation of pharmaceutical interventions and may impair the
comparability of the studies. A comprehensive overview of
used deﬁnitions has been published recently [6].
Due to the inconsistency of deﬁnition we have used the
more general term of DRPs in this publication. A drug-
related problem (DRP) can be deﬁned as an event or cir-
cumstance involving drug therapy that actualy or
potentialy interferes with desired health outcomes [7]. It
represents inefective and unsafe drug use, which may
cause or constitute risk factors for MEs, ADEs, ADRs [8].
After having introduced a clinical pharmacy service on
two wards we documented the efect of a clinical phar-
macist’s interventions on DRPs. The main objective was to
evaluate the practicality of use of the classiﬁcation system
under daily conditions and to explore its usefulness to




Several classiﬁcation systems have been proposed in the
literature, with only some of them being validated [9–11].
We chose the PCNE classiﬁcation system for drug-related
problems (version 5.00) [7], since it contains most of the
required aspects described in a late review of classiﬁcation
systems [12]. To our knowledge the system has been used
in primary care but not in hospital setings. To support
continuity of care one single system for the documentation
of clinical pharmacy activities is desirable. The PCNE
system atributes four items to each observation—(1)
coding for the problem itself, (2) the actual or suspected
cause of the problem, (3) the intervention required to
resolve the DRP, and (4) its outcome. An example to
ilustrate this code is given in Fig.1.
Study design and seting
We conducted a prospective, observational study of clinical
pharmacy interventions in a tertiary 700-bed university
hospital seting. The two observed wards (42 and 43 beds)
included patients in general internal medicine, gastroen-
terology, oncology, nephrology and haematology.
During the period between May to December 2005
(32 weeks) one senior clinical pharmacist (ML) conducted
70 observation days taking part in clinical ward rounds and
reviewing daily al the non-formulary prescriptions and the
case notes of one of ﬁve nursing subunits of the ward
(representing 10–15 patients). Al clinical pharmaceutical
interventions were classiﬁed as DRPs according to the
PCNE System V5.00 and then entered into an Excel spread
sheet (Microsoft Corp., Redmond, Oregon) including the
drugs involved.
Acceptance of pharmacists’ interventions
In the PCNE classiﬁcation the items 11.3–11.5 were al
considered suitable for a modiﬁcation in therapy. Inter-
ventions at prescriber level proposing an approved change
in drug therapy, were classiﬁed at drug level in order to get
more detailed information.
The case:
An elderly patient is treated for parkinsonism with amantadin
500 mg tid. She shows symptoms like weakness and con-
fusion, which are suggestive for signs of an amantadin overdose.
According to her actual kidney function
(creatinine concentration in serum 117 µmol/L) a daily dose of 500 mg
is appropriate. The physician agreed with this change of
the dosage.
The Problem:












Fig. 1Example of a pharmaceutical intervention classiﬁed as a drug
related problem according to PCNE Classiﬁcation System V5.00
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The acceptance rate was calculated as the sum of
interventions with PCNE codes 11.3 and 13.x divided by
the sum of al interventions proposing modiﬁcations
(PCNE codes 11.3, 11.4, 11.5, and 13.x).
Cost avoidance
The cost avoidance of interventions directly linked to a
reduction in medication usage was calculated. These
interventions were: switching from i.v. to p.o. of the same
drug (represented by PCNE code P2.2 [Inappropriate drug
form] in combination with C1.3 [More cost-efective drug
available]), dose reductions (P3.2 [Drug dose too high] in
combination with 13.2 [Dosage changed]) and stopping
unnecessary medications (13.5 [Drug stopped]). For the
calculation we presumed that inappropriate drug therapies
would have continued for three days without being detec-
ted. As an assumption, we counted reduction of dosage as
half price. Drug costs were calculated on the basis of
deﬁned daily doses and ofﬁcial prices given in the Swiss
Drug Formulary [13]. In order to get a yearly estimate, al
the directly cost-linked interventions during the 70 obser-
vation days were added up to a year of 365 working days.
Results
Classiﬁcation of drug-related problems
In the observation period, 1, 444 patients were discharged
from the two wards representing 17,476 patient days. There
were 0.15 interventions per patient counting up to 1.22
interventions per 100 patient days.
A total of 213 pharmaceutical interventions were
recorded, whereof 33 (15.5%) were initiated on ward
rounds, 128 (60.1%) on case note review, 32 (15.0%) as a
consequence of speciﬁc requests and 20 (9.4%) interven-
tions by non-formulary drug orders. To each intervention a
cause and a problem code could be atributed except six
cases (2.8%) without a suitable problem category. The non-
classiﬁed problems are listed in Table1.
Problems
The major DRPs identiﬁed were related to incorect drug
choice (PCNE-Code P2) in 38% (n=81); 24% (n=52)
were drug dosage problems (P3), folowed by drug-drug or
drug-food interactions (P5) in 17% (n=37). ADRs (P1)
accounted for 10% (n=22) of the problems. The detailed
analysis of the 207 DRPs are shown in Table2: potential
drug interactions (16.4%,n=34; P5.1) are most frequent,
folowed by overdose (14.5%,n=30; P3.2) and inap-
propriate choice of drug form (12.6%,n=26, P2.2), 20
(9.7%) problems regarding too low a dose (P3.1), 15
(7.2%) observations with no clear indication for drug use
(P2.5) and 14 (6.8%) non-alergic ADRs (P1.1).
Causes
The overview of the causes (n=213) shows a majority
(68%,n=145) that was related to the selection of the drug
and/or dosage schedule (C1). The second most common
cause with 15% (n=33) involved the drug use process
(C2), i.e., administration and timing of drugs. Patient fac-
tors (C4) seemed to play a minor role (1%,n=2). Aspects
concerning information about the treatment (C3), logistics
(C5), e.g., availability of drugs, and other causes (C6) were
noted each in 11 cases (5%).
The detailed analysis of the causes (Table3) shows that
pharmacokinetics due to organ dysfunction and interac-
tions (C1.4) played a major role (19%) folowed by
inappropriate timing of administration and dosing intervals
(C2.1; 11%,n=24) and inappropriate drug selection
(C1.1; 10%,n=22).
Inverventions
Al of the causes led to an intervention (n=213).Most of
them took place at the drug level (13; 54%,n=116),
folowed by interventions at the prescriber level e.g.
explaining a drug-drug interaction (11; 32%,n=69). The
rest of interventions were at the patient/carer level (12) or
‘other activity’ (14), each resulting in 7% (n=14) of
interventions (Table4).
Table 1Problems which could not be classiﬁed by the PCNE-System
No. Cause Intervention Drug Description of problems
1 C2.1 13.4 Tamsulosin Drug should be taken before the meals
2 C2.1 13.4 Isoniazid/Pyrazinamid/Rifampin Drug should be taken before the meals
3 C2.1 13.4 Lipase/Amylase/Protease Drug should be taken before the meals
4 C2.1 13.4 Piperacilin/Tazobactam Drug should not be administered paralel to a certain
other drug (incompatibility problem)
5 C3.1 12.2 Fluorouracil Topical cytostatic drug, special instructions for use must be folowed
6 C5.2 13.1 Irbesartan Obvious prescribing eror (no more details available)
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Acceptance indicator
In the PCNE classiﬁcation the items 11.3 to 11.5 and al the
interventions at drug level (13.x) can be considered as
propositions for a modiﬁcation in therapy (changes in drug
prescription or other non-pharmacological measures such
as the monitoring of drug levels or other laboratory
parameters) subjected to physician’s approval. In our
sample 148 interventions of 213 concerned therapy modi-
ﬁcations (69%). 83% were adopted by physicians (PCNE
Codes 11.3/13.x, 6% were rejected (11.4), and in 16 cases
(11%) the outcome remained unknown (11.5) (Fig.2).
The remaining 65 interventions are not subject to phy-
sician approval. Almost half of these (47.7%,n=31)
involved giving more information to the prescriber, typi-
caly about potential drug-drug interactions requiring
closer clinical patient monitoring. Another twelve inter-
ventions were ADRs reported to the pharmacovigilance
centre.
Cost avoidance
A total of 51 interventions (24%) were considered to be
directly related to a cost saving without afecting quality of
care (Table5).
Of these 51 cost-relevant interventions 22 (43.1%)
accounted for stopping of medication, which was no longer
required, 16 (31.4%) for switching from i.v. to p.o. medi-
cations and 13 (25.5%) for dosage adjustments.
The interventions stopping unnecessary drugs showed a
mean saving of€10.11 resulting in€1,158 for the period of
one year (365 working days). Interventions which switched
Table 2Detected drug-related problems (n=207), classiﬁed according to PCNE-Classiﬁcation V5.0 [11]
Primary domain Code Detailed classiﬁcation n %
1. Adverse reactions P1 Total 22 10
Patient sufers from an adverse drug event P1.1 Side efect sufered (non-alergic) 14 6.8
P1.2 Side efect sufered (alergic) 5 2.4
P1.3 Toxic efects sufered 3 1.4
2. Drug choice problem P2 Total 81 38
Patient gets or is going to get a wrong (or no
drug) drug for his/her disease
and/or condition
P2.1 Inappropriate drug (not most 11 5.3
P2.2 Inappropriate drug form (not most appropriate for indication) 26 12.6
P2.3 Inappropriate duplication of therapeutic group or active ingredient 7 3.4
P2.4 Contra-indication for drug (incl. Pregnancy/breast feeding) 12 5.8
P2.5 No clear indication for drug use 15 7.2
P2.6 No drug prescribed but clear indication 10 4.8
3. Dosing problem P3 Total 52 24
Patient gets more or less than the
amount of drug he/she requires
P3.1 Drug dose too low or dosage 20 9.7
P3.2 Drug dose too high or dosage regime too frequent 30 14.5
P3.3 Duration of treatment too short 0 0.0
P3.4 Duration of treatment too long 2 1.0
4. Drug use problem P4 Total 7 3.4
Wrong or no drug taken/administered P4.1 Drug not taken/administered at al 6 2.9
P4.2 Wrong drug taken/administered 1 0.5
5. Interactions P5 Total 37 17
There is a manifest or potential drug-drug
or drug-food interaction
P5.1 Potential interaction 34 16.4
P5.2 Manifest interaction 3 1.4
6. Others P6 Total 8 3.9
P6.1 Patient dissatisﬁed with therapy despite taking drug(s) corectly 4 1.9
P6.2 Insufﬁcient awareness of health and diseases (possibly leading to future
problems)
2 1.0
P6.3 Unclear complaints. Further clariﬁcation necessary 1 0.5
P6.4 Therapy failure (reason unknown) 1 0.5
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an i.v. drug to p.o. (n=13) resulted in a mean cost saving
of€93.30 per intervention, i.e.,€7,785 annualy. Assuming
that dose reductions equate to half the price of the daily
regular dose of a drug for three treatment days, dose
adjustments for the 13 interventions led to a cost reduction
of€343 for al and€26.35 per single dose adjustment. Over
Table 3Causes for drug-related problems (n=213), classiﬁed according to PCNE-Classiﬁcation V05 [11]
Primary domain Code Detailed classifcation N %
1. Drug/dose selection C1 Total 145 68
The cause of the DRP is related to the selection
of the drug and/or dosage schedule
C1.1 Inappropriate drug selection 22 10.3
C1.2 Inappropriate dosage selection 15 7.0
C1.3 More cost-efective drug available 18 8.5
C1.4 Pharmacokinetic problems, incl. ageing/ deterioration
in organ function and interactions
41 19.2
C1.5 Synergistic/preventive drug required and not given 6 2.8
C1.6 Deterioration/improvement of disease state 17 8.0
C1.7 New symptom or indication revealed/presented 12 5.6
C1.8 Manifest side efect, no other cause 14 6.6
2. Drug use process C2 Total 33 15
The cause of the DRP can be related to the
way the patient uses the drug, in spite of
proper dosage instructions (on the label)
C2.1 Inappropriate timing of administration and/or dosing
intervals
24 11.3
C2.2 Drug underused/under-administered 2 0.9
C2.3 Drug overused/over-administered 1 0.5
C2.4 Therapeutic drug monitoring required 1 0.5
C2.5 Drug abused (unregulated overuse) 1 0.5
C2.6 Patient unable to use drug/form as directed 4 1.9
3. Information C3 Total 11 5.2
The cause of the DRP can be related to a
lack or misinter pretation of information
C3.1 Instructions for use/taking not known 6 2.8
C3.2 Patient unaware of reason for drug treatment 0 0.0
C3.3 Patient has difﬁculties reading/understanding patient
information form/leaﬂet
1 0.5
C3.4 Patient unable to understand local language 0 0.0
C3.5 Lack of communication between healthcare
professionals
4 1.9
4. Patient/psychological C4 Total 2 1
The cause of the DRP can be related to the
personality or behaviour of the patient
C4.1 Patient forgets to use/take drug 0 0.0
C4.2 Patient has concerns with drugs 0 0.0
C4.3 Patent suspects side-efect 0 0.0
C4.4 Patient unwiling to cary ﬁnancial costs 0 0.0
C4.5 Patient unwiling to bother physician 0 0.0
C4.6 Patient unwiling to change drugs 0 0.0
C4.7 Patient unwiling to adapt life-style 0 0.0
C4.8 Burden of therapy 1 0.5
C4.9 Treatment not in line with health beliefs 0 0.0
C4.10 Patient takes food that interacts with drugs 1 0.5
5. Logistics C5 Total 11 5.2
The cause of the DRP can be related to the logistics of the
prescribing or dispensing mechanism
C5.1 Prescribed drug not available 6 2.8
C5.2 Prescribing eror (only in case of slip of the pen) 4 1.9
C5.3 Dispensing eror (wrong drug or dose dispensed) 1 0.5
6. Others C6 Total 11 5.2
C6.1 Other cause; specify 1 0.5
C6.2 No obvious cause 10 4.7
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the course of one year, the dose adjustment savings equal
€1,788.
Together, the cost-relevant interventions equal€10,731
for one year as mere cost avoidance not counting the efect
on length of stay, ADE rate and possible litigation costs.
Discussion
Our study shows that of 213 interventions by the clinical
pharmacist (CP) almost al (97.8%) could be documented
and rated with the PCNE 5.00 system. By far the most
DRPs were found in the realm of drug prescription. The
classiﬁcation of each DRP on four diferent levels (prob-
lem-cause-intervention-outcome) gives enough details
alowing qualitative and economic analyses. As the PCNE
system has been created for the documentation of DRPs in
the public pharmacy seting, certain items are lacking for
in-patients. Typical DRPs in the hospital seting like
incompatibilities, application erors or faulty transcriptions
cannot be coded in a satisfactory way; this should be taken
into consideration when developing further versions of
PCNE. The primary domain of the problems’ section ‘drug
use problem’ is too restrictive and should be adapted for
the in-hospital seting. Alenet et al. suggest such a
documentation system. In their proposed intervention sec-
tion it contains items often used like ‘administration mode
optimisation’ or ‘change of administration route’, and in
the problems section ‘improper administration’ [10]. A
major draw-back of their system is that neither a descrip-
tion of the cause nor options for the documentation of
interventions at the patient level are provided. Combining
the PCNE system with these elements would create a wel-
adapted tool. Future work should additionaly address the
assessment of DRP severity and the clinical impact of the
pharmacist’s intervention as proposed in literature [14–16].
Time is a key aspect for the acceptance of a documen-
tation system. Practicability of the PCNE system in daily
routine proved to be easy to use and barely time-consum-
ing. The daily documentation classifying the DRP and
entering the PCNE codes and the drugs into the database
(Excel spreadsheet) took only a few minutes.Gansousing
the PI-Doc system on a Microsoft Access database mea-
sured on average 1.9 min for the classiﬁcation and 6.5 min
for the electronic documentation/intervention [17].
The documentation of DRPs with the PCNE system in
everyday practice seems to provide realistic and compa-
rable data about the impact of clinical pharmacy services
on drug treatment. The acceptance of the pharmacist’s






Primary domain Code Intervention n %
No intervention I0.0 No intervention 0 0.0
1. At prescriber level 11 Total 69 32
11.1 Prescriber informed only 31 14.6
11.2 Prescriber asked for information 6 2.8
11.3 Intervention proposed, approved by Prescriber 7 3.3
11.4 Intervention proposed, not approved by Prescriber 9 4.2
11.5 Intervention proposed, outcome unknown 16 7.5
2. At patient/carer level 12 Total 14 6.6
12.1 Patient (medication) counseling 4 1.9
12.2 Writen information provided only 10 4.7
12.3 Patient refered to prescriber 0 0.0
12.4 Spoken to family member/caregiver 0 0.0
3. At drug level 13 Total 116 54
13.1 Drug changed 22 10.3
13.2 Dosage changed 28 13.1
13.3 Formulation changed 10 4.7
13.4 Instructions for use changed 27 12.7
13.5 Drug stopped 22 10.3
13.6 New drug started 7 3.3
4. Other intervention or activity 14 Total 14 6.5
14.1 Other intervention (specify) 2 0.9
14.2 Side efect reported to authorities 12 5.6



















































Fig. 2Types of pharmaceutical
interventions and their
acceptance by the prescribers
Table 5Cost avoidance by clinical pharmaceutical interventions
PCNE Code No. of observations Avoided costs (€) One year estimate (365 days;€)
Stopping unnecessary drugs 13.5 22 (43.1%) 222a 1,158
Switching from i.v. to p.o. [P2.2+C1.3] 16 (31.4%) 1,493b 7,785
Dose adjustments [P3.2+13.2] 13 (25.5%) 343c 1,788
Total 51 (100%) 2058 10,731
aAssuming continued application of this drug for another 3 days
bAssuming continuation of 3 days i.v. therapy
c3 days’ treatment at 50% price
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other studies. A review of 23 studies found an average
acceptance rate of 85.5% [18]. Some studies, however,
may show acceptance rates of up to 99%, but the provision
of drug information was also counted as an intervention,
whereas in our calculation this item (PCNE 11.1: Pre-
scriber informed only) was not included [19].
Clinical pharmacy service can reduce drug costs. Our
study of a single CP’s activity showed a cost avoidance of
over 10,000€/year. Twenty-ﬁve percent of interventions
had direct inﬂuence on drug costs, a similar rate to the
study of McMulin with 26% [20]. A recent study from
Denmark assessed the cost efects of a clinical pharmacist
in a controled prospective study [21]. Cost reductions
resulted in 43% of the interventions with total savings of
direct drug costs of 3442€within one year. The diference
to our ﬁndings showing cost savings up to more than
10,000€/year can be explained by methodological difer-
ences. Our results base on assumptions for calculation.
Minor changes in the assumptions would lead to diferent
results. Second, we extrapolate from our study period of 70
observation days in a period of 8 months to a whole year of
365 working days. In such a design random efects may
occur (one single case with extraordinary high costs or cost
savings) which are then extrapolated to one year.
But in spite of these restrictions, our ﬁndings do not seem
unrealistic in comparison to other studies.Gansofound cost
reductions ranging from 17 to 27€/intervention on average
in four different wards (3 surgery wards, 1 endocrinology
ward) [17] whereas we calculated 34€/intervention. In
particular the cost savings of switching from i.v. to p.o.
application is wel within the range of former results. Our
study conﬁrmsRuetimann’scost savings of 93€per switch
of antibiotics [22]. Our estimations stil are conservative
taken into account we assumed work during daytime only.
Our study has several limitations. A major limitation is the
possible bias in the detection and classiﬁcation of DRPs since
al the pharmaceutical interventions derive from a single site,
a single medical ﬂoor and only one person identiﬁed,
resolved and classiﬁed the DRPs. Using a crossover design
with two pharmacists and kappa statistics would substan-
tialy reduce this bias. Local stafﬁng restrictions
unfortunately did not alow us to folow such a design. Fur-
thermore, results from wards of other medical specialties
should be compared to the medical wards in our study. Third,
we show cost avoidance by the CP’s interventions. The use of
biling data, outcome measures and adjustment for age,
gender and casemix, would enable real costs to be computed.
Conclusion
In conclusion, we consider the PCNE system with the four
levels of classiﬁcation a very useful and easy-to-use tool
for the documentation of clinical pharmacy services not
only for research purposes but also in daily hospital prac-
tice. Data generated by such a documentation system are
increasingly important to provide information on the
impact of the clinical pharmaceutical services supplied and
identiﬁcation of staf needs [23].
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